stockrow
Friday 6 November 2026
Export STAA’s income statement to Excel — free account
STAAR Surgical Company
STAA Healthcare Medical Instruments & Supplies
STAAR Surgical Company’s revenue for fiscal 2025 (year ended December 2025) was $239.4 million, down 23.7% from fiscal 2024.
- Revenue
- −12.0%
- EPS
- −38.9%
- Free cash flow
- +1,378.7%
Quarter to September 2026, against a year earlier
25.27
1.45
−5.43%
Follow STAA
Alert me
| Sep '26 From the 10-Q filed 4 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 409.86 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
3.48 | 4.25 | 3.21 | 4.78 | |
P/FCF ratio |
64.33 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
41.84 | 73.32 | (43.02) | (292.42) | |
P/B ratio |
3.04 | 3.95 | 2.65 | 3.33 | |
Price to Tangible BV |
3.05 | 3.97 | 2.66 | 3.34 | |
EV/Sales |
2.95 | 3.81 | 2.76 | 4.13 | |
EV/EBITDA |
41.73 | 55.79 | 0.00 | 0.00 | |
EV/Operating CF |
45.22 | (397.73) | (15.95) | (28.91) | |
EV/FCF |
54.47 | (189.32) | (14.54) | (24.65) | |
Quick Ratio |
3.88 | 3.81 | 4.02 | 3.47 | |
Current Ratio |
4.68 | 4.66 | 5.12 | 4.55 | |
Net Debt/EBITDA |
0.00 | (13.53) | (13.33) | 7.54 | |
Debt/Assets |
0.00% | 0.00% | 6.91% | 7.19% | |
Debt/Equity |
0.00 | 0.00 | 0.09 | 0.09 | |
Asset Turnover |
0.70 | 0.74 | 0.64 | 0.50 | |
Operating CF/Net income |
4.90 | 2.44 | (4.17) | 0.21 | |
Capex/Depreciation |
0.00 | (0.15) | (0.22) | (0.74) | |
Research and Development Expense of Revenue |
0.00% | 10.63% | 10.61% | 15.99% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 53.12% | 44.41% | 78.60% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
6.61% | 7.01% | 5.16% | 14.90% | |
Graham Net Nets |
0.21 | 0.16 | 0.23 | 0.18 | |
Graham Number |
0.00 | 3.38 | 0.00 | 0.00 | |
Earnings Yield |
0.00% | 0.24% | (2.30%) | (7.06%) | |
Free Cash Flow Yield |
1.55% | (0.47%) | (5.90%) | (3.51%) | |
Revenue per Share |
1.65 | 1.86 | 1.87 | 1.17 | |
Operating CF per Share |
0.54 | 0.39 | (0.43) | (0.08) | |
Capex per Share |
(0.02) | (0.01) | (0.01) | (0.03) | |
Free Cash Flow per Share |
0.52 | 0.38 | (0.44) | (0.11) | |
Cash per Share |
4.08 | 3.61 | 3.28 | 3.78 | |
Shareholders Equity per Share |
7.44 | 7.26 | 7.06 | 6.94 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.44 | 7.26 | 7.06 | 6.94 | |
Free Cash Flow |
26.38 | 19.20 | (22.14) | (5.59) | |
Working Capital |
277.89 | 268.96 | 251.40 | 243.04 | |
Capital Expenditures |
(0.93) | (0.49) | (0.44) | (1.68) | |
Net Current Asset Value |
244.40 | 232.55 | 213.65 | 204.05 | |
EV/EBIT |
1,380.21 | 94.19 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.00 | 0.03 | |
Price to Operating Income |
1,630.18 | 105.13 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
73.32 | 66.46 | 60.56 | 63.98 | |
Average Payables |
11.71 | 12.91 | 10.08 | 14.14 | |
Average Inventory |
49.16 | 49.97 | 48.96 | 49.40 | |
Average Assets |
470.76 | 456.49 | 454.24 | 480.60 | |
Average Common Equity |
364.95 | 350.99 | 351.17 | 370.76 |
Columns are period end dates · fundamentals updated 4 Nov 2026